Novartis Balances 29-Year Dividend Growth with Cell and Gene Therapy Investments

Novartis has recorded its 29th consecutive annual dividend increase, extending a nearly three-decade payout track record. The company reports reaching key operational and financial milestones earlier than planned, including margin-related targets. Novartis highlights growth in its cell and gene therapy business, with Zolgensma sales and related pipeline programs progressing. The mix of long-running dividend consistency and earlier-than-expected operational milestones presents Novartis as a large-cap pharmaceutical group with both income and growth angles.